Emerging drugs for the treatment of myasthenia gravis-Reference-Cited by-同舟云学术

Emerging drugs for the treatment of myasthenia gravis

Published:2021-07-03 Issue:3 Volume:26 Page:259-270
ISSN:1472-8214
Container-title:Expert Opinion on Emerging Drugs
language:en
Short-container-title:Expert Opinion on Emerging Drugs

Author:

Menon Deepak¹,Urra Pincheira Alejandra¹,Bril Vera¹

Affiliation:

1. Department of Medicine, Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Canada

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14728214.2021.1952982

Reference122 articles.

1. Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

2. A systematic review of population based epidemiological studies in Myasthenia Gravis

3. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals

4. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study

5. Quality of life and life circumstances in German myasthenia gravis patients

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Applied Clinical Pharmacology in the Advancement of Rare and Ultra‐Rare Disease Therapeutics;Clinical Pharmacology & Therapeutics;2024-07-22

2. Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy;Journal of Clinical Medicine;2024-06-04

3. A multicenter, randomized, open‐label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis;European Journal of Neurology;2024-05-10

4. Promising therapies for the treatment of myasthenia gravis;Expert Opinion on Pharmacotherapy;2024-03-03

5. How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?;Muscle & Nerve;2024-02-03